Band 1 – Litigation: White-Collar Crime & Government Investigations - District of Columbia
Chambers USA 2020-2021

Sources praise Alice Fisher as “fantastic to work with, especially when dealing with government agencies,” adding that “as a former high-ranking DOJ official she brings a lot of credibility and has excellent strategic thinking skills.” She is a “go-to” “trusted adviser” with “incredible judgment and great instincts” who “does an excellent job of predicting where the other side is going to go.” Her “résumé is second to none.”
Chambers USA 2018-2021

Alice S. Fisher

Washington, D.C.
  • 555 Eleventh Street, NW
  • Suite 1000
  • Washington, D.C. 20004-1304
  • USA

Alice Fisher is a partner in Latham’s Washington, D.C. office and a former member of the firm’s Executive Committee. She focuses her practice on white collar criminal investigations and internal investigations, and advises clients on a range of criminal matters and civil government enforcement matters.

Ms. Fisher has significant experience with corporate investigations and enforcement matters and frequently provides strategic counsel to corporations on managing the legal risks of operating in a global economy. She has particular experience in:

  • International criminal matters relating to alleged bribery under the Foreign Corrupt Practices Act (FCPA) and other anti-corruption laws, economic and export sanctions, and other cross border investigations
  • Criminal and civil fraud matters such as healthcare fraud, accounting and securities fraud, and procurement fraud
  • Government enforcement inquiries and investigations in front of the US Department of Justice (DOJ), including the Drug Enforcement Administration (DEA), the Securities and Exchange Commission (SEC), the Consumer Fraud Protection Bureau, and Congress

From 2005-2008, Ms. Fisher served as assistant attorney general in charge of the Criminal Division of the US DOJ. As assistant attorney general, Ms. Fisher led more than 750 attorneys and staff responsible for federal criminal enforcement policy as well as handling criminal matters in federal courts across the country in all areas of federal criminal law enforcement.

Under her leadership, the Criminal Division pursued a broad array of federal criminal investigations and prosecutions, with particular focus on corporate fraud matters, including securities fraud, procurement fraud, financial institution fraud, anti-money laundering, healthcare fraud, computer hacking and cyber security, national security, as well as US-domestic and international corruption.

Ms. Fisher also chaired the National Procurement Fraud Task Force, supervised the Medicare Fraud Strike Force, and served as a member of the President's Corporate Fraud Task Force.

She handled various transnational and multinational law enforcement operations and policies, including bilateral agreements and treaties involving information sharing and global criminal enforcement initiatives. Representing the DOJ in front of Congress, Ms. Fisher testified on criminal enforcement policies and served on the Federal Criminal Rules Committee.

Ms. Fisher previously held other positions in government, including deputy special counsel to a US Senate Special Committee.

Ms. Fisher has published articles and spoken on criminal law topics such as the criminalization of corporate conduct, the FCPA, healthcare and procurement fraud, the False Claims Act, the US criminal enforcement environment, public corruption and the honest services statute, financial crime in the financial services industry, securities fraud, identity theft, cybercrime, and national security. She is also an elected member of The American Law Institute.

Ms. Fisher’s recent experience includes the representation of:

  • Multiple global pharmaceutical companies in SEC and DOJ FCPA investigations resulting in settlement resolutions and declinations of prosecutions
  • A global payments company in criminal and civil investigations relating to consumer fraud, BSA, and anti-money laundering regulations, resulting in global settlement with DOJ, FTC, and FinCen
  • A global financial institution in FCPA and anti-corruption investigations, including advice to the Board and conducting a global risk assessment
  • A pharmaceutical company in a criminal and civil investigation relating to misbranding and anti-kickback compliance
  • A global pharmaceutical company in an investigation involving the World Bank
  • A global manufacturing company in investigations responding to whistleblower allegations involving alleged bribery
  • Several global manufacturing companies in criminal corruption investigations and obtaining two declinations of prosecution
  • A government contracting company in internal investigations relating to billing and corruption issues
  • A global financial institution relating to international internal and DOJ investigations involving sanctions and anti money laundering issues
  • A hospital chain in national civil and criminal healthcare fraud investigations
  • A private equity group in an accounting fraud investigation
  • A hospital chain in civil qui tam litigation involving anti-kickback statute and billing issues, and successfully obtaining DOJ’s decision not to intervene
  • Several individuals in criminal investigations involving issues relating to campaign finance and corruption
  • A global chemical company in a US$90 billion false claims action resulting in a court order of dismissal
  • A consulting company involved in a criminal investigation involving national security issues
  • A foreign oil services company in US criminal investigation involving corruption allegations, resulting in a declination
  • A foreign oil services company relating to criminal investigation and resolution involving violations of economic sanctions
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.